CN117653627A

CN117653627A - Application of guaiane type sesquiterpene derivative in preparation of antitumor drugs

Info

Publication number: CN117653627A
Application number: CN202311592223.7A
Authority: CN
Inventors: 胡立宏; 刘健; 康迪; 王平; 崔珍珍; 孙玉; 林伟江
Original assignee: Nanjing University of Chinese Medicine
Current assignee: Nanjing University of Chinese Medicine
Priority date: 2023-11-24
Filing date: 2023-11-24
Publication date: 2024-03-08

Abstract

The invention discloses application of a guaiane type sesquiterpene derivative in preparing an anti-tumor medicament, wherein the guaiane type sesquiterpene derivative is shown in a general formula I, and has strong tumor inhibiting activity in hot tumor models such as liver cancer, colorectal cancer, lymphoma and the like by inhibiting chemotaxis of MDSCs to tumor microenvironment and improving infiltration of CD8+ T cells, so that the anti-tumor effect is improved.

Description

Application of guaiane type sesquiterpene derivative in preparation of antitumor drugs

Technical Field

The invention relates to application of guaiane type sesquiterpene derivatives in preparation of antitumor drugs.

Background

Malignant tumors have been severely threatening the life health of humans, and it is statistically that at least 15-20% of cancer patient deaths worldwide are associated with persistent infections and chronic inflammation. Chronic inflammation is one of the ten major features of tumors, and the large number of inflammatory cells present in the tumor microenvironment plays an important role in tumorigenesis and development.

Guaiane sesquiterpene lactones as an important class of natural products have a variety of pharmacological activities. The antitumor drug of the market above, guaiane type Bei-hemiterpene lactone Argentin (Arg):

studies report that Arg achieves antitumor effects by inhibiting farnesyl transferase (FTase) from blocking farnesylation of H-Ras proteins; however, in vitro experiments showed that Arg inhibits farnesylated IC of H-Ras protein ₅₀ Only on the micromolar scale, the mechanism of action cannot fully support the anti-tumor effect in vivo, and the application to tumor indications needs further optimization.

Another guaiane-type sesquiterpene lactone compound is michelia lactone (MCL):

in vitro cell models report that MCL can inhibit tumor cells by exerting cytotoxin effect, especially on tumor stem cellsGrowth of IC thereof ₅₀ At the micromolar level. MCL can promote maturation of DCs, presenting DAMPs signals to immune cells such as T, B, which mediate immunogenic cell death, but promoting maturation of DCs at low T cell activation levels results in MCL with poor anti-HCC activity. In vivo pharmacodynamics evaluation study of liver cancer is carried out, single-dose MCL (30 mg/kg) is continuously administered for 14 days by intraperitoneal injection, and the tumor weight inhibition rate of the Hepa1-6 transplanted tumor model is only 50%. In the HepG2 and Huh7 liver cancer cell transplantation tumor model of the immunized normal mice inoculated with human sources, the intraperitoneal injection administration has the effective dose of up to 25mg/kg. Therefore, there is a need for new derivatives with improved structure, activity and pharmaceutical properties in the field of antitumor.

Disclosure of Invention

The invention aims to: the invention aims to provide an application of a guaiane type sesquiterpene derivative with higher chemical stability and stronger tumor inhibiting activity in preparing an anti-tumor medicament.

The technical scheme is as follows: the invention discloses application of a guaiane type sesquiterpene derivative in preparing an anti-tumor medicament, wherein the guaiane type sesquiterpene derivative is shown in a general formula I:

wherein R is ₁ 、R ₂ Together form a double bond; or R is ₁ Is hydrogen or deuterium, R ₂ Is thatWherein R is ₃ And R is ₄ Respectively C ₁ ～C ₃ Alkyl, or R ₃ 、R ₄ And N atoms form a 5-6 membered cyclic structure, preferably a 5-6 membered cyclic structure selected from: pyrrole, proline, piperidine, piperazine, morpholine;

R ₅ is hydroxy, methoxy, methyl ester, halogen, or-OCONR ₆ R ₇ Wherein R is ₆ Is hydrogen, C ₁ ～C ₆ An alkyl group; r is R ₇ Is C ₁ ～C ₆ Alkyl, fluoro substituted C ₁ ～C ₃ Alkyl, cyclopropane, hydroxy-substituted C ₁ ～C ₆ Alkyl, methoxy substituted C ₁ ～C ₆ Alkyl, dimethylaminoethyl and morpholine substituted C ₁ ～C ₆ Alkyl, piperazine substituted C ₁ ～C ₆ Alkyl, phenyl ring substituted methyl; or R is ₆ 、R ₇ And N atoms form a substituted 5-to 6-membered cyclic structure, preferably selected from: pyrrole, piperidine, piperazine, morpholine; or the 3-position carbon atom and the 4-position carbon atom are connected to form a double bond; or the 4-position carbon atom and the 5-position carbon atom are connected to form a double bond;

R ₈ is hydrogen or hydroxy;

R ₉ is methyl, R ₁₀ And R is R ₁₁ Are connected into cyclopropane; or the 1-position carbon atom and the 10-position carbon atom are connected to form a double bond.

Preferably, the cancer is hepatocellular carcinoma, colorectal cancer or lymphoma.

Preferably, the guaiane sesquiterpene derivative is shown as a general formula II:

R ₁ 、R ₂ together form a double bond; or R is ₁ Is hydrogen or deuterium, R ₂ Is thatWherein R is ₃ And R is ₄ Respectively C ₁ ～C ₃ Alkyl, or R ₃ 、R ₄ And N atoms form a 5-6 membered cyclic structure selected from pyrrole, proline, piperidine, piperazine, morpholine;

R ₅ is methyl; r is R ₆ Is hydroxy, methoxy, methyl ester, halogen; or the 3-position carbon atom and the 4-position carbon atom are connected to form a double bond; or the 4-position carbon atom and the 5-position carbon atom are connected to form a double bond;

R ₇ is hydrogen or hydroxy;

R ₈ is methyl group；R ₉ And R is R ₁₀ The connection forms cyclopropane.

Preferably, the guaiane sesquiterpene derivative is shown in a general formula III:

R ₁ 、R ₂ together form a double bond; or R is ₁ Is hydrogen or deuterium, R ₂ Is thatWherein R is ₃ And R is ₄ Respectively C ₁ ～C ₃ Alkyl, or R ₃ 、R ₄ And the N atom forms pyrrole;

R ₅ is-OCONR ₆ R ₇ Wherein R is ₆ Is hydrogen, C ₁ ～C ₆ An alkyl group; r is R ₇ Is C ₁ ～C ₆ Alkyl, fluoro substituted C ₁ ～C ₃ Alkyl, cyclopropane, hydroxy-substituted C ₁ ～C ₆ Alkyl, methoxy substituted C ₁ ～C ₆ Alkyl, dimethylaminoethyl and morpholine substituted C ₁ ～C ₆ Alkyl, piperazine substituted C ₁ ～C ₆ Alkyl, phenyl ring substituted methyl; or R is ₆ 、R ₇ And N atoms form a substituted 5-to 6-membered cyclic structure, preferably selected from: pyrrole, piperidine, piperazine, morpholine;

preferably, the preparation method of the guaiane type sesquiterpene lactone derivative of the general formula III or the pharmaceutically acceptable salt thereof comprises the following steps:

wherein R is ₁ 、R ₂ 、R ₅ Is as defined in claim 4;

the active ester is obtained by condensation reaction of michelia lactone MCL, wherein the condensing agent is selected from N, N-carbonyl di (1, 2, 4-triazate)Azole), the catalyst is selected from pyridine and 4-dimethylaminopyridine, and the solvent is selected from dichloromethane. The activated ester is not purified and is combined with NHR ₆ R ₇ The reaction produces an intermediate III-A, wherein the base of the reaction is selected from N, N-diisopropylethylamine, and the solvent is selected from dichloromethane. Intermediate III-A, and NHR ₃ R ₄ The target compound III is obtained, the base of the reaction is selected from potassium carbonate, and the solvent is selected from dichloromethane.

Preferably, the guaiane-type sesquiterpene derivatives are the following compounds:

preferably, the pharmaceutically acceptable salt comprises hydrochloride, sulfate, phosphate, maleate, fumaric acid or hydrochloride.

Preferably, the pharmaceutically acceptable salt is fumaric acid or hydrochloride:

the invention also discloses a medicinal composition, which comprises the guaiane type sesquiterpene derivative shown in the general formula I or pharmaceutically acceptable salt thereof, a pharmaceutically acceptable carrier and a combined immune checkpoint inhibitor thereof.

Preferably, the combined immune checkpoint inhibitor is anti-PD-L1/PD-1 mab or anti-CTLA-4 mab.

The invention also discloses application of the medicinal composition in preparing antitumor drugs.

The principle of the invention: the application of the guaiane type sesquiterpene derivative in preparing antitumor drugs can inhibit the chemotaxis of MDSCs to the tumor microenvironment by reducing the expression of the CCR2 on the surface of the MDSCs and improve the infiltration of CD8+ T cells, thereby improving the antitumor effect. MDSCs are a group of cells from an inhibitory myeloid system, and play a role in negative immune regulation by inhibiting T cell function and proliferation, so that the derivative of the general formula I has strong tumor inhibition activity in a thermal tumor model with T lymphocyte infiltration, such as liver cell carcinoma, colorectal cancer or lymphoma.

In addition, the derivative of the general formula I is combined with fumarate or hydrochloride, and the related salt type compound can improve the oral absorption of the compound, so that the strong tumor inhibiting activity can be achieved on a Hepa1-6 mouse tumor model, an H22 mouse subcutaneous tumor model and a CT26 colon cancer cell mouse tumor model. The combined immune checkpoint inhibitor can achieve a synergistic effect. T lymphocytes are a group of immune cells capable of recognizing and killing tumors, and on one hand, the tumor cells can specifically bind to PD-1 of the T lymphocytes by expressing PD-L1, so that the tumor killing function of the T lymphocytes is inhibited, and immune escape is realized. On the other hand, tumor cells antagonize the effects of T lymphocytes by secreting cytokines to recruit immunosuppressive cells such as MDSCs. Therefore, the combination of the guaiane sesquiterpene derivative and the immune checkpoint inhibitor can simultaneously relieve the inhibition effect between MDSCs-T cells and tumor cells-T cells and play a synergistic anti-tumor role.

The beneficial effects are that: compared with the prior art, the invention has the following remarkable advantages: (1) Has better treatment effect on liver cancer, colorectal cancer or lymphoma and other thermal tumors; compound 57 (40. Mu. Mol/kg/d) was given by gavage, with a tumor inhibition rate of up to 96.78% in the Hepa1-6 mouse engraftment model; at a concentration of 10 mu M, the inhibition rate of the compound 33 on the chemotaxis of myeloid-derived suppressor cells MDSCs can reach 83.3% at most; (2) The combined immune checkpoint inhibitor can synergistically enhance the anti-tumor effect obviously; the compound 57 (1 mg/kg/d) is injected intraperitoneally and combined with the anti-PD-L1 monoclonal antibody (5 mg/kg/d), and the tumor inhibition rate can reach 96.99% at the highest on the Hepa1-6 mouse transplantation tumor model; (3) The derivatives of the invention show very low toxicity when applied to anti-tumor treatment.

Drawings

FIG. 1 is a guaiane-type sesquiterpene derivative of formula I;

FIG. 2 is a plot of compound 33 and compound 70 concentrations in HEPES7.4 solution over time;

FIG. 3 is a plot of compound 33 and compound 70 concentrations in mouse plasma over time.

Detailed Description

The technical scheme of the invention is further described below with reference to the accompanying drawings.

Example 1

Preparation of parthenolide:

pulverizing dried root bark of Magnolia amurensis into coarse powder, soaking in 10 times of 95% ethanol for 12 hr, reflux-extracting under heating for 2 hr twice, filtering, mixing filtrates, concentrating under reduced pressure, and drying to obtain Magnolia amurensis crude extract. Refining by silica gel column chromatography, gradient eluting with petroleum ether-ethyl acetate, collecting fraction rich in parthenolide and costunolide, mixing, concentrating, and recrystallizing to obtain parthenolide with a yield of 4.0% and a purity of 96.3%. ¹ H NMR(500MHz,CDCl ₃ ):δ6.31(d,J＝2.9Hz,1H),5.62(d,J＝3.4Hz,1H),5.20(d,J＝11.8Hz,2H),3.85(t,J＝8.6Hz,1H),2.78(d,J＝8.9Hz,1H),2.45-2.32(m,2H),2.22-2.10(m,4H),1.70(s,3H),1.69-1.66(m,1H),1.29(s,3H),1.27-1.18(m,1H)。ESI-MS(m/z):[M+H] ⁺ ＝249.1(calcd:249.1)。

Example 2

Compounds 1 to 70 were prepared from the parthenolide obtained in example 1.

250mL round bottom burnDichloromethane (100 mL), p-toluenesulfonic acid (250 mg,1.45 mmol) and parthenolide (10 g,40.32 mmol) were added sequentially to the flask and stirred at room temperature until TLC detection was complete. The reaction solution was washed with water (20 mL. Times.3) and saturated brine (20 mL. Times.3) in this order, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and separated by silica gel column chromatography to give the intermediate michelia lactone MCL, yield: 90%. ¹ H NMR(500MHz,CDCl ₃ ):δ6.21(d,J＝3.5Hz,1H),5.51(d,J＝3.0Hz,1H),3.81(t,J＝10.5Hz,1H),2.73(d,J＝10.5Hz,1H),2.68-2.64(m,2H),2.42-2.37(m,1H),2.26-2.16(m,3H),2.11-2.08(m,1H),1.83-1.75(m,2H),1.69(s,3H),1.31(s,3H),1.27-1.25(m,1H)。ESI-MS(m/z):[M+Na] ⁺ ＝271.1(calcd:271.1)。

Preparation of Compound 1:

MCL (100 mg,0.40 mmol), methylene chloride (1.0 mL), N-carbonylbis (1, 2, 4-triazole) (131 mg,0.80 mmol), pyridine (64 mg,0.8 mmol) and 4-dimethylaminopyridine (4 mg,0.04 mmol) were sequentially added to a 5mL reaction flask, and stirred at room temperature until TLC detection was completed to obtain a crude intermediate solution. N, N-diisopropylethylamine (52 mg,0.4 mmol) and aqueous methylamine (47. Mu.L, 0.60mmol,40% aqueous solution) were added in this order, and stirred at room temperature until TLC detection was completed. The reaction solution was diluted with ethyl acetate (10 mL), washed successively with water (10 ml×3), a saturated citric acid solution (10 ml×3), a saturated copper sulfate solution if the subsequent product contains a basic group, a saturated sodium bicarbonate solution (10 ml×3), and a saturated brine (10 ml×3), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and separated by silica gel column chromatography to give compound 1 in a yield of 72%. ¹ H NMR(500MHz,CDCl ₃ ):δ6.19(d,J＝3.5Hz,1H),5.47(d,J＝3.0Hz,1H),4.73(s,1H),3.80(t,J＝10.5Hz,1H),3.11(d,J＝9.5Hz,1H),2.74(d,J＝4.5Hz,3H),2.70-2.65(m,1H),2.48-2.43(m,2H),2.28-2.20(m,3H),2.11-2.02(m,2H),1.72(s,3H),1.53(s,3H),1.40-1.32(m,1H)。ESI-MS(m/z):[M+H] ⁺ ＝306.16(calcd:306.16)。

Preparation of compound 2:

the preparation method of the compound 2 refers to the compound 1, and the yield is 72%. ¹ H NMR(500MHz,CDCl ₃ ):δ6.20(d,J＝3.5Hz,1H),5.48(d,J＝3.0Hz,1H),4.76(s,1H),3.80(t,J＝10.5Hz,1H),3.21-3.11(m,3H),2.76-2.66(m,1H),2.48-2.43(m,2H),2.28-2.20(m,3H),2.12-2.06(m,2H),1.72(s,3H),1.53(s,3H),1.40-1.32(m,1H),1.14(t,J＝7.0Hz,3H)。ESI-MS(m/z):[M+H] ⁺ ＝320.18(calcd:320.18)。

Preparation of compound 3:

the preparation method of the compound 3 refers to the compound 1, and the yield is 76%. ¹ H NMR(500MHz,CDCl ₃ ):δ6.20(d,J＝3.5Hz,1H),5.47(d,J＝3.0Hz,1H),4.80(s,1H),3.80(t,J＝10.5Hz,1H),3.14-3.05(m,3H),2.70-2.66(m,1H),2.48-2.41(m,2H),2.27-2.21(m,3H),2.11-2.05(m,2H),1.72(s,3H),1.53(s,3H),1.55-1.48(m,2H),1.40-1.32(m,1H),0.92(t,J＝7.5Hz,3H)。ESI-MS(m/z):[M+H] ⁺ ＝334.19(calcd:334.19)。

Preparation of Compound 4:

the preparation method of the compound 4 refers to the compound 1, and the yield is 74%. ¹ H NMR(500MHz,CDCl ₃ ):δ6.17(d,J＝3.5Hz,1H),5.46(d,J＝3.0Hz,1H),4.78(s,1H),3.79(t,J＝10.5Hz,1H),3.17-3.10(m,3H),2.69-2.64(m,1H),2.46-2.41(m,2H),2.26-2.18(m,3H),2.10-2.04(m,2H),1.71(s,3H),1.51(s,3H),1.48-1.44(m,2H),1.37-1.31(m,3H),0.91(t,J＝7.5Hz,3H)。ESI-MS(m/z):[M+H] ⁺ ＝348.21(calcd:348.21)。

Preparation of compound 5:

the preparation method of the compound 5 refers to the compound 1, and the yield is 41%. ¹ H NMR(500MHz,CDCl ₃ ):δ6.20(d,J＝3.5Hz,1H),5.48(d,J＝3.0Hz,1H),4.66(s,1H),3.83-3.74(m,2H),3.13(d,J＝10.0Hz,1H),2.71-2.66(m,1H),2.48-2.44(m,2H),2.29-2.20(m,3H),2.13-2.05(m,2H),1.73(s,3H),1.53(s,3H),1.41-1.33(m,1H),1.16(t,J＝7.0Hz,6H)。ESI-MS(m/z):[M+H] ⁺ ＝334.19(calcd:334.19)。

Preparation of Compound 6:

the preparation method of the compound 6 refers to the compound 1, and the yield is 33%. ¹ H NMR(500MHz,CDCl ₃ ):δ6.16(d,J＝3.5Hz,1H),5.44(d,J＝3.0Hz,1H),4.51(d,J＝9.0Hz,1H),3.77(t,J＝10.5Hz,1H),3.39-3.38(m,1H),3.19-3.17(m,1H),2.68-2.63(m,1H),2.45-2.34(m,2H),2.24-2.21(m,3H),2.17-2.06(m,2H),1.70(s,3H),1.54-1.47(m,2H),1.49(s,3H),1.41-1.30(m,3H),0.92-0.86(m,6H)。ESI-MS(m/z):[M+H] ⁺ ＝362.23(calcd:362.23)。

Preparation of compound 7:

the preparation method of the compound 7 refers to the compound 1, and the yield is 69%. ¹ H NMR(500MHz,CDCl ₃ )δ6.19(d,J＝3.3Hz,1H),5.47(d,J＝3.0Hz,1H),5.01(s,1H),3.80(t,J＝10.1Hz,1H),3.09(s,1H),2.71-2.62(m,1H),2.56(s,1H),2.50-2.41(m,2H),2.32-2.16(m,3H),2.13-1.99(m,2H),1.72(s,3H),1.53(s,3H),1.39-1.32(m,1H),0.69(d,J＝6.8Hz,2H),0.53(s,2H)。ESI-MS(m/z):[M+H] ⁺ ＝332.18(calcd:332.18)。

Preparation of Compound 8:

the preparation method of the compound 8 refers to the compound 1, and the yield is 71%. ¹ H NMR(500MHz,CDCl ₃ ):δ6.13(d,J＝3.5Hz,1H),5.42(d,J＝3.0Hz,1H),5.30(s,1H),4.66(s,1H),3.75(t,J＝10.5Hz,1H),3.63-3.61(m,1H),3.24-3.20(m,1H),3.13-3.11(m,1H),2.63-2.59(m,1H),2.54-2.47(m,2H),2.40-2.28(m,2H),2.20-2.15(m,3H),2.06-1.98(m,2H),1.64(s,3H),1.42(s,3H),1.33-1.26(m,1H)。ESI-MS(m/z):[M+H] ⁺ ＝336.17(calcd:336.17)。

Preparation of Compound 9:

the preparation method of the compound 9 refers to the compound 1, and the yield is 62%. ¹ H NMR(500MHz,CDCl ₃ ):δ6.21(d,J＝3.5Hz,1H),5.49(d,J＝3.0Hz,1H),3.83(t,J＝10.5Hz,1H),3.68(t,J＝5.5Hz,2H),3.37-3.26(m,2H),3.19(d,J＝10.5Hz,1H),2.71-2.67(m,1H),2.48-2.44(m,1H),2.40-2.37(m,1H),2.29-2.20(m,3H),2.16-2.10(m,2H),1.72(s,3H),1.71-1.68(m,2H),1.51(s,3H),1.40-1.35(m,1H)。ESI-MS(m/z):[M+H] ⁺ ＝350.19(calcd:350.19)。

Preparation of compound 10:

the preparation method of the compound 10 refers to the compound 1, and the yield is 59%. ¹ H NMR(500MHz,CDCl ₃ ):δ6.18(d,J＝3.5Hz,1H),5.47(d,J＝3.0Hz,1H),5.06(s,1H),4.49(s,1H),3.79(t,J＝10.5Hz,1H),3.62(t,J＝6.5Hz,2H),3.15-3.10(m,3H),2.68-2.64(m,1H),2.45-2.38(m,2H),2.25-2.22(m,3H),2.10-2.04(m,2H),1.70(s,3H),1.60-1.55(m,2H),1.53-1.50(m,2H),1.49(s,3H),1.43-1.33(m,3H)。ESI-MS(m/z):[M+H] ⁺ ＝377.24(calcd:377.24)。

Preparation of Compound 11:

the preparation method of the compound 11 refers to the compound 1, and the yield is 75%. ¹ H NMR(500MHz,CDCl ₃ ):δ6.20(d,J＝3.5Hz,1H),5.47(d,J＝3.0Hz,1H),5.51(s,1H),3.80(t,J＝10.5Hz,1H),3.48-3.46(m,2H),3.37(s,3H),3.36-3.29(m,2H),3.14(d,J＝10.0Hz,1H),2.71-2.66(m,1H),2.48-2.42(m,2H),2.27-2.20(m,3H),2.12-2.03(m,2H),1.73(s,3H),1.55(s,3H),1.40-1.32(m,1H)。ESI-MS(m/z):[M+H] ⁺ ＝350.19(calcd:350.19)。

Preparation of Compound 12:

the preparation method of the compound 12 refers to the compound 1, and the yield is 74%. ¹ H NMR(500MHz,CDCl ₃ )δ6.20(d,J＝3.3Hz,1H),5.48(d,J＝3.0Hz,1H),5.06(s,1H),3.80(t,J＝10.1Hz,1H),3.46(t,J＝5.8Hz,2H),3.35(s,3H),3.29-3.21(m,2H),3.14(d,J＝10.1Hz,1H),2.71-2.66(m,1H),2.48-2.41(m,2H),2.27-2.20(m,3H),2.12-2.04(m,2H),1.80-1.76(m,2H),1.73(s,3H),1.53(s,3H),1.40-1.33(m,1H)。ESI-MS(m/z):[M+H] ⁺ ＝364.20(calcd:364.20)。

Preparation of Compound 13:

the preparation method of the compound 13 refers to the compound 1, and the yield is 62%. ¹ H NMR(500MHz,CDCl ₃ ):δ6.20(d,J＝3.5Hz,1H),5.56(s,1H),5.49(d,J＝3.0Hz,1H),3.82(t,J＝10.5Hz,1H),3.62-3.58(m,4H),3.36-3.34(m,2H),3.12(d,J＝10.5Hz,1H),2.98-2.87(m,1H),2.71-2.66(m,1H),2.48-2.43(m,2H),2.27-2.20(m,3H),2.13-1.97(m,3H),1.72(s,3H),1.52(s,3H),1.40-1.32(m,1H)。ESI-MS(m/z):[M+H] ⁺ ＝380.20(calcd:380.20)。

Preparation of compound 14:

the preparation method of the compound 14 refers to the compound 1, and the yield is 61%. ¹ H NMR(500MHz,CDCl ₃ ):δ6.20(d,J＝3.5Hz,1H),5.48(d,J＝3.0Hz,1H),5.22(s,1H),3.80(t,J＝10.5Hz,1H),3.31-3.22(m,2H),3.16(d,J＝10.0Hz,1H),2.70-2.67(m,1H),2.48-2.40(m,4H),2.34-2.20(m,3H),2.26(s,6H),2.11-2.04(m,2H),1.72(s,3H),1.55(s,3H),1.39-1.32(m,1H)。ESI-MS(m/z):[M+H] ⁺ ＝363.22(calcd:363.22)。

Preparation of compound 15:

the preparation method of the compound 15 refers to the compound 1, and the yield is 71%. ¹ H NMR(500MHz,CDCl ₃ ):δ6.18(d,J＝3.5Hz,1H),5.46(d,J＝3.0Hz,1H),5.18(s,1H),3.79(t,J＝10.5Hz,1H),3.72-3.70(m,4H),3.25-3.23(m,2H),3.17(d,J＝9.5Hz,1H),2.70-2.66(m,1H),2.48-2.37(m,8H),2.26-2.19(m,3H),2.12-2.07(m,2H),1.71(s,3H),1.53(s,3H),1.39-1.31(m,1H)。ESI-MS(m/z):[M+H] ⁺ ＝405.23(calcd:405.23)。

Preparation of Compound 16:

the preparation method of the compound 16 refers to the compound 1, and the yield is 69%. ¹ H NMR(500MHz,CDCl ₃ ):δ7.35-7.30(m,4H),7.28-7.25(m,1H),6.20(d,J＝3.5Hz,1H),5.48(d,J＝3.0Hz,1H),5.13(s,1H),4.43-4.39(m,1H),4.30-4.26(m,1H),3.81(t,J＝10.5Hz,1H),3.18(d,J＝9.5Hz,1H),2.68-2.65(m,1H),2.49-2.42(m,2H),2.28-2.21(m,3H),2.17-2.06(m,2H),1.73(s,3H),1.56(s,3H),1.40-1.32(m,1H)。ESI-MS(m/z):[M+H] ⁺ ＝382.19(calcd:382.19)。

Preparation of compound 17:

the preparation method of the compound 17 refers to the compound 1, and the yield is 70%. ¹ H NMR(500MHz,CDCl ₃ ):δ6.20(d,J＝3.5Hz,1H),5.48(d,J＝3.0Hz,1H),3.83(t,J＝10.5Hz,1H),3.07(d,J＝10.0Hz,1H),2.96(s,3H),2.89(s,3H),2.72-2.66(m,1H),2.54-2.44(m,2H),2.30-2.21(m,3H),2.14-2.09(m,1H),2.03-1.97(m,1H),1.73(s,3H),1.54(s,3H),1.42-1.34(m,1H)。ESI-MS(m/z):[M+H] ⁺ ＝320.18(calcd:320.18)。

Preparation of compound 18:

the preparation method of the compound 18 refers to the compound 1, and the yield is 69%. ¹ H NMR(500MHz,CDCl ₃ ):δ6.20(d,J＝3.5Hz,1H),5.48(d,J＝3.0Hz,1H),3.83(t,J＝10.5Hz,1H),3.41-3.35(m,1H),3.30-3.22(m,3H),3.06(d,J＝10.0Hz,1H),2.72-2.67(m,1H),2.57-2.53(m,1H),2.49-2.44(m,1H),2.30-2.22(m,3H),2.14-2.09(m,1H),2.04-1.97(m,1H),1.73(s,3H),1.55(s,3H),1.42-1.34(m,1H),1.14(s,6H)。ESI-MS(m/z):[M+H] ⁺ ＝348.21(calcd:348.21)。

Preparation of compound 19:

the preparation method of the compound 19 refers to the compound 1, and the yield is 71%. ¹ H NMR(500MHz,CDCl ₃ ):δ6.20(d,J＝3.5Hz,1H),5.48(d,J＝3.0Hz,1H),3.82(t,J＝10.5Hz,1H),3.53-3.49(m,1H),3.37-3.30(m,3H),3.10(d,J＝10.0Hz,1H),2.72-2.66(m,1H),2.53-2.44(m,2H),2.29-2.21(m,3H),2.13-2.08(m,1H),2.07-2.00(m,1H),1.88-1.83(m,4H),1.73(s,3H),1.56(s,3H),1.42-1.34(m,1H)。ESI-MS(m/z):[M+H] ⁺ ＝346.19(calcd:346.19)。

Preparation of compound 20:

the preparation method of the compound 20 refers to the compound 1, and the yield is 68%. ¹ H NMR(500MHz,CDCl ₃ ):δ6.20(d,J＝3.5Hz,1H),5.47(d,J＝3.0Hz,1H),3.82(t,J＝10.5Hz,1H),3.51-3.42(m,4H),3.10(d,J＝10.0Hz,1H),2.72-2.68(m,1H),2.52-2.44(m,2H),2.30-2.22(m,3H),2.14-2.01(m,2H),1.73(s,3H),1.60-1.56(m,6H),1.53(s,3H),1.41-1.35(m,1H)。ESI-MS(m/z):[M+H] ⁺ ＝360.21(calcd:360.21)。

Preparation of compound 21:

the preparation method of the compound 21 refers to the compound 1, and the yield is 67%. ¹ H NMR(500MHz,CDCl ₃ ):δ6.19(d,J＝3.5Hz,1H),5.47(d,J＝3.0Hz,1H),4.24-4.12(m,2H),3.81(t,J＝10.5Hz,1H),3.08(s,1H),2.83-2.67(m,3H),2.51-2.43(m,2H),2.29-2.20(m,3H),2.12-2.09(m,1H),2.05-1.99(m,1H),1.72(s,3H),1.65-1.60(m,2H),1.55-1.48(m,1H),1.52(s,3H),1.41-1.33(m,1H),1.19-1.04(m,2H),0.94(d,J＝6.5Hz,3H)。ESI-MS(m/z):[M+H] ⁺ ＝374.23(calcd:374.23)。

Preparation of compound 22:

the preparation method of the compound 22 refers to the compound 1, and the yield is 52%. ¹ H NMR(500MHz,CDCl ₃ ):δ6.20(d,J＝3.5Hz,1H),5.48(d,J＝3.0Hz,1H),3.83(t,J＝10.5Hz,1H),3.57-3.40(m,4H),3.08(d,J＝10.0Hz,1H),2.71-2.67(m,1H),2.53-2.46(m,2H),2.43-2.38(m,3H),2.32(s,3H),2.30-2.22(m,4H),2.13-2.10(m,1H),2.04-2.02(m,1H),1.73(s,3H),1.53(s,3H),1.42-1.37(m,1H)。ESI-MS(m/z):[M+H] ⁺ ＝375.22(calcd:375.22)。

Preparation of compound 23:

the preparation method of the compound 23 refers to the compound 1, and the yield is 55%. ¹ H NMR(500MHz,CDCl ₃ ):δ6.20(d,J＝3.5Hz,1H),5.48(d,J＝3.0Hz,1H),3.82(t,J＝10.5Hz,1H),3.71-3.41(m,4H),3.08(d,J＝10.0Hz,1H),2.71-2.66(m,1H),2.52-2.43(m,8H),2.29-2.22(m,3H),2.13-2.10(m,1H),2.07-2.00(m,1H),1.72(s,3H),1.52(s,3H),1.42-1.34(m,1H),1.11(t,J＝7.0Hz,3H)。ESI-MS(m/z):[M+H] ⁺ ＝389.24(calcd:389.24)。

Preparation of compound 24:

the preparation method of the compound 24 refers to the compound 1, and the yield is 71%. ¹ H NMR(500MHz,CDCl ₃ ):δ6.18(d,J＝3.5Hz,1H),5.47(d,J＝3.0Hz,1H),3.81(t,J＝10.5Hz,1H),3.68-3.62(m,5H),3.49-3.41(m,3H),3.06(d,J＝10.0Hz,1H),2.70-2.64(m,1H),2.51-2.44(m,2H),2.28-2.21(m,3H),2.13-2.00(m,2H),1.72(s,3H),1.52(s,3H),1.40-1.33(m,1H)。ESI-MS(m/z):[M+H] ⁺ ＝362.19(calcd:362.19)。

Preparation of compound 25:

the preparation method of the compound 25 refers to the compound 1, and the yield is 75%. ¹ H NMR(500MHz,CDCl ₃ )δ6.17(d,J＝3.3Hz,1H),5.46-5.45(m,1H),4.82(s,1H),3.78(t,J＝10.1Hz,1H),3.13(d,J＝9.9Hz,1H),3.02-2.97(m,1H),2.90-2.85(m,1H),2.71-2.62(m,1H),2.48-2.35(m,2H),2.26-2.17(m,3H),2.12-2.02(m,2H),1.77-1.71(m,1H),1.70(s,3H),1.51(s,3H),1.38-1.30(m,1H),0.89(d,J＝6.7Hz,6H)。ESI-MS(m/z):[M+H] ⁺ ＝348.21(calcd:348.21)。

Preparation of compound 26:

/>

the preparation of compound 26 was carried out in 78% yield with reference to compound 1. ¹ H NMR(500MHz,CDCl ₃ )δ6.20(d,J＝3.3Hz,1H),5.83(t,J＝56.1Hz,1H),5.48(d,J＝2.9Hz,1H),5.16(s,1H),3.80(t,J＝10.1Hz,1H),3.62-3.38(m,2H),3.11(d,J＝10.5Hz,1H),2.73-2.62(m,1H),2.48-2.41(m,2H),2.27-2.20(m,3H),2.12-1.99(m,2H),1.72(s,3H),1.53(s,3H),1.38-1.31(m,1H)。ESI-MS(m/z):[M+H] ⁺ ＝356.16(calcd:356.16)。

Preparation of compound 27:

the preparation method of the compound 27 refers to the compound 1, and the yield is 67%. ¹ H NMR(500MHz,CDCl ₃ )δ6.17(d,J＝3.2Hz,1H),5.46(d,J＝3.0Hz,1H),3.80(t,J＝10.0Hz,1H),3.37-3.12(m,2H),3.10-3.00(m,1H),2.88(d,J＝28.6Hz,3H),2.72-2.62(m,1H),2.54-2.41(m,2H),2.29-2.18(m,3H),2.11-2.07(m,1H),2.02-1.93(m,1H),1.71(s,3H),1.63-1.53(m,2H),1.51(s,3H),1.40-1.32(m,1H),0.88(t,J＝7.4Hz,3H)。ESI-MS(m/z):[M+H] ⁺ ＝348.21(calcd:348.21)。

Preparation of Compound 28:

the preparation method of the compound 28 refers to the compound 1, and the yield is 68%. ¹ H NMR(500MHz,CDCl ₃ )δ6.19(d,J＝3.3Hz,1H),5.46(d,J＝3.0Hz,1H),3.81(t,J＝10.1Hz,1H),3.44-3.00(m,5H),2.69-2.66(m,1H),2.59-2.42(m,2H),2.29-2.20(m,3H),2.12-2.08(m,1H),2.03-1.97(m,1H),1.72(s,3H),1.61-1.54(m,2H),1.53(s,3H),1.42-1.33(m,1H),1.19-1.07(m,3H),0.89-0.87(m,3H)。ESI-MS(m/z):[M+H] ⁺ ＝362.23(calcd:362.23)。

Preparation of compound 29:

the preparation method of the compound 29 refers to the compound 1, and the yield is 55%. ¹ H NMR(500MHz,CDCl ₃ )δ6.20(d,J＝3.3Hz,1H),5.72(s,1H),5.48(d,J＝3.1Hz,1H),3.81(t,J＝10.1Hz,1H),3.73(t,J＝4.7Hz,4H),3.30-3.12(m,3H),2.72-2.65(m,1H),2.47-2.39(m,8H),2.29-2.20(m,3H),2.14-2.05(m,2H),1.72(s,3H),1.69-1.66(m,2H),1.53(s,3H),1.40-1.34(m,1H)。ESI-MS(m/z):[M+H] ⁺ ＝419.25(calcd:419.25)。

Preparation of compound 30:

the preparation method of the compound 30 refers to the compound 1, and the yield is 47%. ¹ H NMR(500MHz,CDCl ₃ )δ6.17(d,J＝3.3Hz,1H),5.83(s,1H),5.46(d,J＝3.0Hz,1H),3.78(t,J＝10.1Hz,1H),3.26-3.11(m,3H),2.65(t,J＝9.3Hz,1H),2.56-2.36(m,11H),2.26(s,7H),2.12-2.04(m,2H),1.71(s,3H),1.69-1.63(m,2H),1.51(s,3H),1.39-1.32(m,1H)。ESI-MS(m/z):[M+H] ⁺ ＝432.28(calcd:432.28)。

Preparation of Compound 31:

the preparation method of the compound 31 refers to the compound 1, and the yield is 62%. ¹ H NMR(500MHz,CDCl ₃ )δ6.18(d,J＝3.2Hz,1H),5.46(d,J＝3.0Hz,1H),4.28-4.14(m,2H),3.80(t,J＝10.1Hz,1H),3.75-3.68(m,4H),3.06(s,1H),2.92-2.63(m,4H),2.49-2.42(m,2H),2.37-2.18(m,5H),2.14-2.07(m,2H),2.01(d,J＝10.2Hz,1H),1.84-1.82(m,2H),1.71(s,3H),1.49(s,3H),1.46-1.32(m,3H)。ESI-MS(m/z):[M+H] ⁺ ＝445.26(calcd:445.26)。

Preparation of compound 32:

the preparation method of the compound 32 refers to the compound 1, and the yield is 44%. ¹ H NMR(500MHz,CDCl ₃ )δ6.17(d,J＝3.3Hz,1H),5.45(d,J＝3.0Hz,1H),5.22(s,1H),3.78(t,J＝10.1Hz,1H),3.31-3.19(m,2H),3.15(d,J＝9.5Hz,1H),2.83(s,1H),2.67(t,J＝9.4Hz,1H),2.48-2.37(m,11H),2.29(s,3H),2.25-2.18(m,3H),2.11-2.04(m,2H),1.70(s,3H),1.52(s,3H),1.38-1.31(m,1H)。ESI-MS(m/z):[M+H] ⁺ ＝418.26(calcd:418.26)。

Preparation of compound 54:

ethylene glycol dimethyl ether (1.67 mL,21.26 mmol) was added to anhydrous dichloromethane (67 mL) under ice bath and nitrogen protection, and after stirring uniformly, 13.3mL of diethyl zinc solution (1M n-hexane solution) was added thereto, diiodomethane (2.67 mL,3.11 mmol) was slowly added dropwise thereto, and stirring was carried out for 10 minutes to prepare a cyclopropanation reagent. Another round bottom flask was charged with Michelia lactone MCL (300 mg,1.21 mmol) and anhydrous dichloromethane (5 mL), stirred for dissolution, then nitrogen-protected, and placed in an ice bath. The cyclopropanation reagent is added into the substrate solution dropwise, the reaction is continued for 1h after the completion of the dropwise addition, and the reaction is carried out at room temperature overnight. The reaction mixture was quenched with saturated ammonium chloride, filtered, washed successively with water (10 mL. Times.3) and saturated brine (10 mL. Times.3), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and separated by silica gel column chromatography to give intermediate 54-1.

Then 54-1 (100.0 mg,0.38 mmol) and ethanol (2 mL) were added sequentially in a round bottom flask followed by Et in the above solution ₃ N (96.0 mg,0.95 mmol) and L-proline ethyl ester (108.8 mg,0.76 mmol) were reacted by stirring2h. The reaction solution was filtered, washed with water (10 ml×3) and saturated brine (10 ml×3) in this order, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and separated by silica gel column chromatography (petroleum ether: ethyl acetate: triethylamine=1:1:0.02) to give compound 54 in yield: 88%. ¹ H NMR(500MHz,DMSO-d ₆ )δ3.91(t,J＝10.4Hz,1H),3.82-3.76(m,2H),3.30(dd,J＝8.9,4.7Hz,1H),3.08-3.01(m,2H),2.91-2.86(m,1H),2.57-2.52(m,2H),2.06-1.88(m,5H),1.86-1.73(m,4H),1.73-1.62(m,4H),1.41-1.32(m,4H),1.22(t,J＝12.1Hz,3H),1.01(s,3H),0.66(d,J＝4.0Hz,1H),0.39(d,J＝4.2Hz,1H).ESI-MS(m/z):[M+H] ⁺ ＝406.5(calcd:406.54)。

Preparation of compound 55:

in a 5mL reaction flask, compound 20 (100 mg,0.28 mmol) was dissolved in 1mL of methylene chloride, tetrahydropyrrole (197mg, 2.80 mmol) was added, and after stirring for 3 hours, ethyl acetate (10 mL) was diluted, the mixture was washed with water (10 mL. Times.3), saturated sodium bicarbonate solution (10 mL. Times.3) and saturated brine (10 mL. Times.3) in this order, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and separated by silica gel column chromatography to give compound 55 in 66% yield. ¹ H NMR(500MHz,CDCl ₃ )δ3.80(t,J＝10.2Hz,1H),3.57-3.30(m,4H),3.03-2.97(m,1H),2.91-2.81(m,2H),2.59-2.53(m,2H),2.52-2.37(m,5H),2.28-2.14(m,4H),2.14-1.97(m,2H),1.79-1.69(m,8H),1.61-1.53(m,5H),1.52(s,4H)。ESI-MS(m/z):[M+H] ⁺ ＝431.28(calcd:431.28)。

Preparation of compound 56:

/>

starting from compound 20 and dimethylamine hydrochloride, the preparation method is the same as that of compound 55, and the yield of compound 56 is: 85%. ¹ H NMR(500MHz,CDCl ₃ )δ3.82(t,J＝10.1Hz,1H),3.58-3.30(m,4H),3.05-2.96(m,1H),2.74(dd,J＝12.9,4.9Hz,1H),2.60(dd,J＝12.9,6.6Hz,1H),2.53-2.35(m,3H),2.26(s,6H),2.28-2.14(m,4H),2.09-1.97(m,2H),1.74-1.65(m,6H),1.59-1.54(m,6H),1.39-1.27(m,1H)。ESI-MS(m/z):[M+H] ⁺ ＝405.27(calcd:405.27)。

Preparation of hydrochloride 65 of Compound 15

Compound 15 (404 mg,1 mmol) was dissolved in dichloromethane (2 mL), stirred at room temperature for 2h, then hydrochloric acid solution was added dropwise to pH 4-5, filtered, and the obtained solid was washed with dichloromethane to obtain a white solid which was hydrochloride of compound 15 (compound 65) in 86% yield. ¹ H NMR(500MHz,Methanol-d ₄ )δ6.15(d,J＝6.9Hz,1H),5.62(d,J＝14.3Hz,1H),4.14-4.08(m,2H),4.05-3.89(m,1H),3.88-3.76(m,2H),3.65-3.42(m,4H),3.28-3.16(m,3H),2.89-2.71(m,1H),2.57-2.46(m,1H),2.42-2.28(m,4H),2.25-2.15(m,1H),2.09-2.00(m,3H),1.76(s,3H),1.57(s,3H),1.44-1.37(m,1H)。ESI-MS(m/z):[M+H] ⁺ ＝405.23(calcd:405.23)。

Preparation of fumarate salt 66 of Compound 15

Fumaric acid salt compound 66 of 15 was prepared as reference to the preparation of compound 15 hydrochloride salt using fumaric acid instead of hydrochloric acid. The yield thereof was found to be 71%. ¹ H NMR(500MHz,Methanol-d ₄ )δ6.74(s,2H),6.14(d,J＝10.2Hz,1H),5.61(d,J＝10.5Hz,1H),4.01-3.78(m,5H),3.39-3.36(m,2H),3.19(d,J＝11.5Hz,1H),3.11-3.05(m,2H),2.99-2.85(m,4H),2.82-2.72(m,1H),2.52-2.47(m,1H),2.43-2.24(m,4H),2.22-2.13(m,1H),2.06-2.00(m,1H),1.75(s,3H),1.56(s,3H),1.43-1.35(m,1H)。ESI-MS(m/z):[M+H] ⁺ ＝405.23(calcd:405.23)。

Preparation of hydrochloride 67 of Compound 55

Compound 67 was prepared in 91% yield by the method for preparing hydrochloride of reference compound 15 using compound 55 as starting material. ¹ H NMR(500MHz,Methanol-d ₄ )δ4.13(t,J＝10.0Hz,1H),3.81-3.72(m,2H),3.68(s,1H),3.64-3.56(m,1H),3.51-3.39(m,3H),3.26-3.19(m,2H),3.09(d,J＝8.7Hz,2H),2.54-2.40(m,2H),2.34-2.06(m,8H),2.04-1.94(m,2H),1.75(s,3H),1.66-1.60(m,2H),1.55-1.51(m,7H),1.49-1.43(m,1H),1.42-1.26(m,1H)。ESI-MS(m/z):[M+H] ⁺ ＝431.28(calcd:431.28)。

Preparation of fumarate salt 68 of Compound 55

Fumaric acid is used for replacing hydrochloric acid, and the fumarate compound 68 of 55 is prepared according to the preparation method of the hydrochloride of the compound 15, and the yield is 75%. ¹ H NMR(500MHz,Methanol-d ₄ )δ6.72(s,2H),4.17-4.07(m,2H),3.60-3.40(m,9H),3.11-3.01(m,2H),2.52-2.41(m,2H),2.35-2.21(m,3H),2.18-2.12(m,5H),2.02-1.93(m,2H),1.74(s,3H),1.66-1.61(m,2H),1.55-1.52(m,7H),1.49-1.39(m,1H)。ESI-MS(m/z):[M+H] ⁺ ＝431.28(calcd:431.28)。

Preparation of fumarate salt 69 of Compound 56

Fumaric acid is used for replacing hydrochloric acid, and the fumarate compound 69 of 56 is prepared according to the preparation method of the hydrochloride of the compound 15, and the yield is 71%. ¹ H NMR(500MHz,Methanol-d ₄ )δ6.71(s,2H),4.14-4.09(m,1H),3.46-3.40(m,3H),3.31-3.27(m,1H),3.12-3.01(m,2H),2.90(s,6H),2.52-2.42(m,2H),2.34-2.22(m,3H),2.14(q,J＝10.9,10.1Hz,1H),2.01-1.93(m,2H),1.75(s,3H),1.66-1.61(m,2H),1.55-1.51(m,7H),1.48-1.40(m,1H),1.40-1.29(m,2H)。ESI-MS(m/z):[M+H] ⁺ ＝405.27(calcd:405.27)。

The compound 54 is used as a starting material, and the reference compound 15 hydrochloride can be prepared by a preparation method3.82-3.77(m,2H),3.31(dd,J＝8.9,4.7Hz,1H),3.09-3.02(m,2H),2.92-2.87(m,1H),2.58-2.53(m,2H),2.07-1.89(m,5H),1.87-1.74(m,4H),1.75-1.63(m,4H),1.42-1.33(m,4H),1.23(t,J＝12.1Hz,3H),1.02(s,3H),0.67(d,J＝4.0Hz,1H),0.40(d,J＝4.2Hz,1H)。ESI-MS(m/z):[M+H] ⁺ ＝406.5(calcd:406.54)。

Example 3

Solubility test of Compounds in Water

Precisely weighing 20 mug of each of the compounds 15, 20 and 33, and 10mg of each of the compounds 65 to 70, adding the mixture into 1mL of deionized water, and completely dissolving the mixture by ultrasonic treatment. The saturated solution is prepared, filtered and analyzed by HPLC, the sample injection amount is sequentially 1 mu L,3 mu L, 5 mu L, 10 mu L, 15 mu L and 20 mu L, and a standard curve of the corresponding compound is drawn.

Preparing an unsaturated solution of the compound, dissolving for 4 hours under the assistance of ultrasound, standing in a water bath at 37 ℃ for 1 hour, centrifuging the obtained unsaturated solution, removing 30 mu L of supernatant, adding 200 mu L of deionized water for dilution, filtering, analyzing a sample by HPLC, and substituting relevant data into the measured standard curve to obtain the solubility of the test compound 15, 20, 33 and 65-70.

TABLE 1 Water solubility of Compounds

As shown in Table 1, the water solubility of the fumarate or hydrochloride compounds 65-70 was improved by at least 100-fold or more over that of the Argatroban and compounds 15, 20, 33.

Example 4

Conversion of Compound 70 to Compound 33 in plasma and HEPES

HEPES7.4 solution formulation: 1.6g NaCl,0.074g KCl,0.027g Na ₂ HPO ₄ 0.2g of glucose and 1g of 4-hydroxyethyl piperazine ethane sulfonic acid (HEPES) solution were adjusted to pH 7.4 with 0.5M NaOH in 90mL of distilled water, and the volume was fixed with distilled water to 100mL.

Plasma preparation: mouse plasma was taken in an EP tube pre-filled with heparin sodium and centrifuged at 8000rpm for 10min at 4℃and the supernatant was taken.

Sample analysis: 0.6mg of compound 70 was dissolved in 250 μl of deionized water. The samples were added with 250. Mu.L of mouse serum or HEPES7.4 solution, incubated at 37℃and sampled at different time points, 20. Mu.L of the samples were taken in EP tubes, 60. Mu.L of methanol was added, vortexed and homogenized, and centrifuged at 12000rpm for 10min at 4 ℃. At 1h, 2h, 4h, 8h and 12h respectively, the supernatant was taken, samples were analyzed by HPLC, the amount of sample injection was 10. Mu.L, and the corresponding peak areas were recorded. The chromatographic conditions were as follows: the column was Hanbang C18 (4.6X250 mm,5 μm); the mobile phase is acetonitrile: 10mmol/mL ammonium formate solution = 60:40, a step of performing a; the flow rate is 1.0mL/min; the detection wavelength is 210nm; column temperature was 30 ℃.

As shown in FIG. 1, the compound 33 was contained in the HEPES buffer solution at 4.88%, 9.31%, 20.8%, 42.4% and 60.0% in 1h, 2h, 4h, 8h and 12h. The results of this experiment demonstrate that compound 70 can be converted as a prodrug to the original compound 33 in HEPES buffer solution. As shown in fig. 2, the content of compound 33 in the plasma of the mice was gradually increased at 1h, 2h, 4h, 8h, and 12h, and the contents were 5.51%, 9.45%, 21.6%, 48.3%, and 59.6%, respectively, and the experimental results showed that compound 70 was also converted into original compound 33 as a prodrug in the plasma of the mice.

Similarly, prodrug compounds 67, 68, 69 may also be converted to the corresponding prodrug compound 20 in plasma and HEPES.

Example 5

Compound inhibition MDSCs (MDSCs) experiment for promoting T cell proliferation

Mice were sacrificed by cervical dislocation and immersed in 75% ethanol solution for 5min. The tibia of the mice was removed under sterile conditions, both ends of the bone were cut off, the medium was aspirated with a 1mL syringe, and the bone marrow was repeatedly rinsed into a 15mL centrifuge tube. Bone marrow cells were collected by centrifugation at 1600rpm for 5min, washed twice with 1 XPBS, resuspended in cell culture dishes with RPMI 1640 complete medium containing the cytokines GM-CSF (10 ng/mL) and IL-4 (10 ng/mL), and stimulated bone marrow cells to differentiate into MDSCs. MDSCs were then treated with DMSO (negative control), 1. Mu.M of 1-70 compounds, respectively, for 12h. Simultaneously, separating connective tissue below the spleen by forceps, taking out the spleen, placing the spleen into a sterile culture dish containing 5mL of RPMI 1640 culture medium, placing the spleen on a 200-mesh cell screen, lightly grinding the spleen by using a 10mL syringe needle core, simultaneously sucking a small amount of RPMI 1640 culture medium to wash the cell screen, and washing the spleen cell suspension into a 15mL centrifuge tube; centrifuging at 1600rpm for 5min, collecting T cells, washing twice with 1 XPBS, re-suspending the T cells obtained by centrifugation with 1mL PBS, adding 1mL of 10 mu M CFDA-SE solution, incubating at room temperature for 8min, and adding 10mL of PRMI 1640 complete medium after incubation is finished to terminate CFDA-SE staining; centrifugation at 1600rpm for 5min and 1 XPBS washing twice, cells were resuspended in cell culture dishes at 37℃in 5% CO using RPMI 1640 complete medium containing concanavalin A (5. Mu.g/mL) ₂ Incubator cultures for 12h to stimulate T cell activation. After the drug administration is finished, collecting MDSCs cells into a centrifuge tube, centrifuging at 1600rpm for 5min, removing supernatant, adding 1mL of fresh culture medium for resuspension, placing into a plate, adding 1mL of stimulated and activated T cells (1:1) for co-culture for 48h, after the incubation is finished, collecting the cells into the centrifuge tube, washing with PBS for two times, adding Fc antibody, and incubating for 10min at room temperature in a dark state; adding CD3 labeled flow antibody, incubating at 4deg.C for 30min in dark, washing cells with PBS after incubation, and resuspending cells with 300 μl PBS, and detecting on-flow machine.

As shown in Table 1, in the co-culture model of MDSCs and T cells, all compounds can promote the proliferation of T cells to different degrees, which suggests that the compounds have strong tumor inhibiting activity on tumor models (such as liver cancer, colorectal cancer, lymphoma and the like) with T lymphocyte infiltration. Wherein compounds 15, 20, 33 can significantly promote T cell proliferation, the outcome of which is similar to positive compound Arg.

TABLE 1 influence of Compounds on T cell proliferation in MDSCs and T cell Co-culture models

/>

Note that: "+", compared with the control group, the T cell proliferation rate is in the range of 0-20%; compared with the control group, the proliferation rate of the T cells is between 20 and 40 percent; "+". "+", in comparison with the control group, T cell proliferation rate >40%.

Example 4

Compounds 15, 20, 33 inhibit chemotaxis of MDSCs: uniformly spreading liver cancer cells of the Hepa1-6 mice in a 6-hole plate, sucking the supernatant after the cell wall is full, adding 1-1.5mL of fresh culture medium into each hole, culturing for 24 hours, collecting the supernatant, centrifuging at 160 rpm for 5min, sucking the supernatant, and filtering with a 0.22 mu M filter membrane to obtain a tumor condition culture medium for later use. Mice were sacrificed by cervical dislocation and immersed in 75% ethanol solution for 5min. The tibia of the mice was removed under sterile conditions, both ends of the bone were cut off, the medium was aspirated with a 1mL syringe, and the bone marrow was repeatedly rinsed into a 15mL centrifuge tube. Centrifugation at 1600rpm for 5min to collect bone marrow cells, washing twice with 1 XPBS, resuspension to cells with RPMI 1640 complete medium containing cytokines GM-CSF (10 ng/mL) and IL-4 (10 ng/mL), stimulation of differentiation of bone marrow cells into MDSCs, counting, and adjustment of cell density to 1×10 ⁶ Cells were plated uniformly into 24 well plates at 300 μl/well. MDSCs were treated with DMSO (negative control), 1. Mu.M, 10. Mu.M Arg, 15, 20, 33 for 12h, centrifuged at 160 rpm for 5min, the supernatant removed, and 300. Mu.L fresh medium was added to resuspend cells in a Transwell chamber, and the lower chamber was placed in normal medium (vsLight group), 600 μl of tumor condition medium (model group), co-culture for 24h. After the incubation, the cells were removed, cells entering the lower chamber were counted, and the chemotactic inhibitory effect of Arg, 15, 20, 33 on MDSCs was investigated.

As shown in table 2, in the MDSCs and tumor conditioned medium co-culture model, 15, 20, and 33 significantly inhibited MDSCs chemotaxis compared to the control group, and had concentration dependence. The inhibition of MDSCs chemotaxis by 20 and 33 was better than positive compound Arg at a concentration of 10 μm.

TABLE 2 inhibition of MDSCs chemotaxis by Arg, 15, 20, 33 example 5

Compounds 15, 20, 33 down-regulate CCR2 mRNA levels: mice were sacrificed by cervical dislocation and immersed in 75% ethanol solution for 5min. The tibia of the mice was removed under sterile conditions, both ends of the bone were cut off, the medium was aspirated with a 1mL syringe, and the bone marrow was repeatedly rinsed into a 15mL centrifuge tube. Bone marrow cells were collected by centrifugation at 1600rpm for 5min, washed twice with 1 XPBS, resuspended in cell culture dishes with RPMI 1640 complete medium containing GM-CSF (10 ng/mL) +IL-4 (10 ng/mL), and stimulated to differentiate into MDSCs. Cell count, cell density was adjusted to 1X 10 with complete medium ⁶ Cells were plated uniformly into 6-well plates at a volume of 2mL per well. MDSCs were then treated with DMSO (negative control), 1. Mu.M, 10. Mu.M Arg, 15, 20, 33, respectively, for 2h. After the incubation, the cells were collected in centrifuge tubes, centrifuged at 1600rpm for 5min, washed once with 1 XPBS, and 500. Mu.L of RNA extraction reagent was added to each tube. After centrifugation to obtain a precipitate, 20. Mu.L of DEPC water is added into each tube to dissolve the precipitate, the concentration of RNA is measured, the RNA is reversely transcribed into cDNA, the primer and the reverse transcriptase are added into a 96-well plate, the rotation speed is 4000rpm, the centrifugation is carried out for 5min, the mixture is put into a PCR instrument for detection, and the inhibition effect of Arg, 15, 20 and 33 on the expression of CCR2 mRNA is measured.

As shown in table 3, compounds Arg, 15, 20, 33 all down-regulated CCR2 mRNA levels and were concentration dependent.

TABLE 3 inhibition of CCR2 mRNA levels by Compounds 15, 20, 33

Example 6

Antitumor effects of compounds 57, 66, 69 on the Hepa1-6 mouse subcutaneous engraftment tumor model: in vitro culture and amplification of Hepa1-6 cells, taking appropriate amount of cells in logarithmic phase, and re-suspending in serum-free DMEM culture medium and Matrigel (1:1) suspension, and preparing into 2.5X10 under aseptic condition ⁶ 100. Mu.L of the cell suspension, 100. Mu.L of the cell suspension was inoculated subcutaneously in the anterior left limb axilla of male C57BL/6 mice with a syringe. When the tumor volume grows to 100-200mm ³ At this time, animals with moderate tumor size were selected and randomly grouped, 6 animals per group. The solvent control group, arg group at 40. Mu. Mol/kg/d, compound 57 group, 66 group and 69 group, respectively. The administration was performed by lavage every day for 2 weeks. During the dosing period, mice body weight and tumor diameter were measured daily. Cervical dislocation is killed after the experiment is finished, and tumor taking and weighing are carried out. The calculation formula of Tumor Volume (TV) is: tv=1/2×a×b ² A represents the tumor long diameter; b represents the tumor minor diameter.

As shown in Table 4, arg, 57, 66 and 69 had significant tumor inhibiting effect on the subcutaneous tumor implantation model of the Hepa1-6 mice after 2 weeks of continuous administration.

TABLE 4 anti-tumor Effect of Compounds 57, 66, 69 on the Hepa1-6 mouse transplantation tumor model

* P <0.05; * P <0.01; * P <0.001 (compared to solvent control).

Example 7

Antitumor effects of compounds 57, 66, 69 on H22 mice subcutaneous engraftment tumor model: h22 cells are cultured and amplified in vitro, a proper amount of cells in logarithmic phase are taken and resuspended in serum-free RPMI 1640 culture medium and Matrigel (1:1) suspension, and the cells are prepared into 3 multiplied by 10 under aseptic condition ⁵ 100 mu L of cell suspension, 100 mu L of cell suspension was injected into the cell suspensionL cell suspensions were inoculated subcutaneously into the anterior left limb axilla of male BALB/c mice. When the tumor volume grows to 100-200mm ³ At this time, animals with moderate tumor size were selected and randomly grouped, 6 animals per group. The solvent control group, arg group at 40. Mu. Mol/kg/d, compound 57 group, 66 group and 69 group, respectively. The administration was performed by lavage every day for 2 weeks. During the dosing period, mice body weight and tumor diameter were measured daily. Cervical dislocation is killed after the experiment is finished, and tumor taking and weighing are carried out. The calculation formula of Tumor Volume (TV) is: tv=1/2×a×b ² A represents the tumor long diameter; b represents the tumor minor diameter.

Killing tumor-bearing mice by cervical dislocation, placing in a beaker containing 75% alcohol, peeling off tumor of mice, soaking tumor in 100mm of RPMI 1640 ³ After all tumors were stripped in the petri dishes, nail-sized tumors were excised and transferred to a 1.5mL EP tube, the tumors were minced with scissors, and the minced tumor tissue suspension was transferred to a 15mL centrifuge tube containing 3-5mL digestive enzymes (Collagenase IV 1mg/mL, hyaluronidase 1mg/mL, DNase I20U/mL) and digested with shaking at 200rpm at 37℃for 1h. After digestion, the mixture is screened by a 200-mesh screen to obtain tumor cell suspension. The resulting tumor suspension was centrifuged at 160 rpm for 5min, the supernatant was aspirated, 1mL of 1 XPBS was added to each tube, the cell suspension was transferred to 1.5mL EP tubes, centrifuged at 1600rpm for 5min, the supernatant was removed, 100. Mu.L of 1 XPBS was used to resuspend the cells, 1. Mu.L of dead dye was added to each tube, and after homogenization, incubation was performed at room temperature in the dark for 15min. Simultaneously taking out spleen with forceps, placing into sterile culture dish containing 5mL RPMI 1640 medium, placing spleen on 200 mesh cell screen, lightly grinding spleen with 10mL syringe needle core, sucking small amount of RPMI 1640 medium, washing cell screen, washing spleen cell suspension into 15mL centrifuge tube, centrifuging at 1600rpm for 5min to collect cells, washing with 1×PBS once, and adding 3mL erythrocyte lysate (ddH ₂ O dilution), lysis for 5min, after lysis, 10mL of 1 x PBS was added to each tube to terminate lysis, centrifugation at 1600rpm for 5min, 1mL of 1 x PBS was added to each 15mL centrifuge tube, transferred to 1.5mL EP tube, and centrifugation at 1600rpm for 5min. Adding 1mL1 XPBS to the stained tumor cells and lysed spleen cells, washing once, centrifuging at 1600rpm for 5min, and removingAnd (5) supernatant. Tumor cells and spleen cells were resuspended in 100. Mu.L of 1 XPBS, respectively, and FcX was added to each tube ^TM After the incubation, 1 μl of antibody was incubated at room temperature for 10min in the dark, 1 μl of each of CD45, CD11b, gr1 antibodies was sequentially added to each tube, incubated at 4deg.C for 30min in the dark, washed once with 1×pbs after the incubation, the supernatant was discarded, and the cells were resuspended with 300 μl of 1×pbs, filtered into flow tubes, and detected on-machine.

Killing tumor-bearing mice by cervical dislocation, placing in a beaker containing 75% alcohol, peeling off tumor of mice, soaking tumor in 100mm of RPMI 1640 ³ After all tumors were stripped in the petri dishes, nail-sized tumors were excised and transferred to a 1.5mL EP tube, the tumors were minced with scissors, and the minced tumor tissue suspension was transferred to a 15mL centrifuge tube containing 3-5mL digestive enzymes (Collagenase IV 1mg/mL, hyaluronidase 1mg/mL, DNase I20U/mL) and digested with shaking at 200rpm at 37℃for 1h. After digestion, the mixture is screened by a 200-mesh screen to obtain tumor cell suspension. The resulting tumor suspension was centrifuged at 160 rpm for 5min, the supernatant was aspirated, 1mL of 1 XPBS was added to each tube, the cell suspension was transferred to 1.5mL EP tubes, centrifuged at 1600rpm for 5min, the supernatant was removed, 100. Mu.L of 1 XPBS was used to resuspend the cells, 1. Mu.L of dead dye was added to each tube, and the cells were incubated at room temperature in the absence of light for 15min after homogenization. Simultaneously taking out spleen with forceps, placing into sterile culture dish containing 5mL RPMI 1640 medium, placing spleen on 200 mesh cell screen, lightly grinding spleen with 10mL syringe needle core, sucking small amount of RPMI 1640 medium, washing cell screen, washing spleen cell suspension into 15mL centrifuge tube, centrifuging at 1600rpm for 5min to collect cells, washing with 1×PBS once, and adding 3mL erythrocyte lysate (ddH ₂ O dilution), lysis for 5min, after lysis, 10mL of 1 x PBS was added to each tube to terminate lysis, centrifugation at 1600rpm for 5min, 1mL of 1 x PBS was added to each 15mL centrifuge tube, transferred to 1.5mL EP tube, and centrifugation at 1600rpm for 5min. The stained tumor cells and lysed spleen cells were washed once with 1 XPBS, 1600rpm, and centrifuged for 5min to remove the supernatant. Tumor cells and spleen cells were resuspended in 100. Mu.L of 1 XPBS, respectively, and FcX was added to each tube ^TM 1 mu L of antibody is incubated for 10min at room temperature in a dark place, and after incubation, the antibody is sequentially added to each tube1 μl of each of the CD45, CD3 and CD8 antibodies was added, incubated at 4deg.C for 30min in the absence of light, and after staining, 1mL PBS was added to wash once, at 1600rpm, and centrifuged for 5min. The supernatant was discarded, 300. Mu.L of 1 XPBS was added to resuspend the cells, the cell suspension was filtered and added to the flow tube and checked on-line.

As shown in Table 5, arg, 57, 66 and 69 had tumor-inhibiting effect on H22 mice in the subcutaneous tumor implantation model after continuous administration for 2 weeks.

TABLE 5 anti-tumor Effect of Compounds 57, 66, 69 on H22 mice transplantation tumor model

* P <0.05; * P <0.01; * P <0.001 (compared to solvent control).

As shown in table 6, after the end of the experiment, flow cytometry examined the proportion of MDSCs in tumor tissue and spleen in the H22 mice subcutaneous engraftment tumor model, which was significantly reduced compared to the solvent control group.

TABLE 6 inhibition of MDSCs by Compounds 57, 66, 69 in H22 mouse tumor transplantation model

* P <0.05; * P <0.01; * P <0.001 (compared to solvent control).

As shown in table 7, after the end of the experiment, the ratio of T cells in tumor tissue and spleen in the H22 mice subcutaneous engrafted tumor model was examined by flow cytometry, and the ratio of T cells in tumor tissue and spleen in Arg, 57, 66, 69 dosed groups was significantly increased compared to the solvent control group.

TABLE 7 influence of Compounds 57, 66, 69 on T cells in H22 mouse transplantation tumor model

* P <0.05; * P <0.01; * P <0.001 (compared to solvent control)

Example 8

Antitumor effects of Arg, compound 57 on mouse engraftment tumor model of CT26 colon cancer cells: CT26 cells are cultured and amplified in vitro, a proper amount of cells in logarithmic phase are taken and resuspended in a serum-free RPMI 1640 medium, and 5 multiplied by 10 is prepared under aseptic condition ⁵ 100. Mu.L of the cell suspension, 100. Mu.L of the cell suspension was inoculated subcutaneously in the anterior left limb axilla of male BALB/c mice with a syringe. Until the tumor volume grows to 50-70mm ³ At this time, animals with moderate tumor size were selected and randomly grouped, with 5 animals per group. The solvent control group, the Arg group at 80. Mu. Mol/kg/d, and the compound 57 group, respectively. The administration was performed by lavage each day for 3 weeks. During the dosing period, mice body weight and tumor diameter were measured daily. Cervical dislocation is killed after the experiment is finished, and tumor taking and weighing are carried out. The calculation formula of Tumor Volume (TV) is: tv=1/2×a×b ² A represents the tumor long diameter; b represents the tumor minor diameter.

As shown in Table 8, arg and compound 57 each had an anti-tumor effect on the CT26 mice subcutaneous tumor implantation model after 3 weeks of continuous administration.

TABLE 8 anti-tumor Effect of Arg, compound 57 on CT26 mouse transplantation tumor model

Example 9

Antitumor effects of compounds 57, 66, 69 on 4T1 mouse engraftment tumor model: 4T1 cells are cultured and amplified in vitro, a proper amount of cells in logarithmic phase are taken and resuspended in serum-free RPMI 1640 culture medium and Matrigel (1:1) suspension, and the 4X 10 cells are prepared under aseptic condition ⁵ 100. Mu.L of the cell suspension, 100. Mu.L of the cell suspension was inoculated subcutaneously in the anterior left limb axilla of female BALB/c mice with a syringe. When the tumor volume grows to 100-200mm ³ At this time, animals with moderate tumor size were selected and randomly grouped, with 5 animals per group. Arg group and compound of 40 mu mol/kg/d respectively as solvent control group57, 66, 69. The administration was performed by lavage each day for 3 weeks. During the dosing period, mice body weight and tumor diameter were measured daily. Cervical dislocation is killed after the experiment is finished, and tumor taking and weighing are carried out. The calculation formula of Tumor Volume (TV) is: tv=1/2×a×b ² A represents the tumor long diameter; b represents the tumor minor diameter.

As shown in table 9, arg, 57, 66, 69 had no significant tumor inhibiting effect on the 4T1 mice subcutaneous transplantation tumor model following 3 weeks of continuous administration.

TABLE 9 anti-tumor Effect of Compounds 57, 66, 69 on 4T1 mouse transplantation tumor model

* P <0.05; * P <0.01; * P <0.001 (compared to solvent control).

Example 10

Anti-tumor effect of compound 57 and anti-PD-L1 mab combination on the Hepa1-6 mouse subcutaneous engraftment tumor model: in vitro culture and amplification of Hepa1-6 cells, taking appropriate amount of cells in logarithmic phase, and re-suspending in serum-free DMEM culture medium and Matrigel (1:1) suspension, and preparing into 2.5X10 under aseptic condition ⁶ 100. Mu.L of the cell suspension, 100. Mu.L of the cell suspension was inoculated subcutaneously in the anterior left limb axilla of male C57BL/6 mice with a syringe. When the tumor volume grows to 100-200mm ³ At this time, animals with moderate tumor size were selected and randomly grouped, 6 animals per group. The solvent control group, the compound 57 (1 mg/kg/d) group, the anti-PD-L1 mab 5mg/kg group and the 57 combined anti-PD-L1 mab group are respectively adopted. Compound 57 was intraperitoneally injected daily, and anti-PD-L1 mab was administered once daily for 2 weeks. During the dosing period, mice body weight and tumor diameter were measured daily. Cervical dislocation is killed after the experiment is finished, and tumor taking and weighing are carried out. The calculation formula of Tumor Volume (TV) is: tv=1/2×a×b ² A represents the tumor long diameter; b represents the tumor minor diameter.

On the Hepa1-6 mice subcutaneous tumor implantation model, the tumor inhibition rate of the combined administration group is obviously higher than that of the compound 57 and the anti-PD-L1 monoclonal antibody group after continuous administration for 2 weeks, and the synergistic effect is achieved (table 10).

TABLE 10 anti-tumor Effect of Compound 57 in combination with anti-PD-L1 mab on Hepa1-6 mouse transplantation tumor model

* P <0.05; * P <0.01; * P <0.001 (compared to solvent control).

Example 11

Anti-tumor effect of compound 57 and anti-PD-L1 mab combination on H22 mice subcutaneous engraftment tumor model: h22 cells are cultured and amplified in vitro, a proper amount of cells in logarithmic phase are taken and resuspended in serum-free RPMI 1640 culture medium and Matrigel (1:1) suspension, and the cells are prepared into 2 multiplied by 10 under aseptic condition ⁶ 100. Mu.L of the cell suspension, 100. Mu.L of the cell suspension was inoculated subcutaneously in the anterior left limb axilla of male Balb/c mice with a syringe. When the tumor volume grows to 100-200mm ³ At this time, animals with moderate tumor size were selected and randomly grouped, with 5 animals per group. The solvent control group, the compound 57 (2.5 mg/kg/d) single drug group, the anti-PD-L1 single drug (5 mg/kg) single drug group and the compound 57 combined anti-PD-L1 single drug group are respectively adopted. Compound 57 was injected intraperitoneally every day, and anti-PD-L1 mab was administered once every three days for 2 weeks. During the dosing period, mice body weight and tumor diameter were measured daily. Cervical dislocation is killed after the experiment is finished, and tumor taking and weighing are carried out. The calculation formula of Tumor Volume (TV) is: tv=1/2×a×b ² A represents the tumor long diameter; b represents the tumor minor diameter.

On the H22 mice subcutaneous engrafting tumor model, the tumor suppression rate of the combined administration group is obviously higher than that of the compound 57 and the anti-PD-L1 monoclonal antibody group after continuous administration for 2 weeks, and the synergistic effect is achieved (Table 11).

TABLE 11 anti-tumor Effect of Compound 57 in combination with anti-PD-L1 mab on H22 mouse tumor-transplantation model

* P <0.05; * P <0.01; * P <0.001 (compared to solvent control).

Example 12

Safety inspection of Compound 57

1 experiment reagent: compound 57 (purity > 98%) was prepared according to example 2 above; sodium carboxymethylcellulose (sodium carboxyl methyl cellulose, CMC-Na), national pharmaceutical group chemical company, inc; the remaining reagents were all analytically pure.

2 Experimental methods

2.1 grouping and dosing of mice: female and male C57BL/6 mice, weighing 18-22g, were randomized into the following 3 groups according to body weight size in order to examine the effect of compound 57 on mouse toxicity: normal group, compound 57 (500,100 mg/kg), 10 mice per group, male and female halves. Compound 57 was administered parenterally 1 time a day for 30 consecutive days at a volume of 0.1mL/10g and normal group was given an equal volume of vehicle (physiological saline).

2.2 sample collection: after the last administration, the mixture is kept stand for 2 hours at room temperature from the fundus vein Cong Caixie, centrifuged for 15-20min at the temperature of 1500 rpm and 4 ℃, and the upper serum is carefully sucked and split charging is carried out, and the mixture is frozen at the temperature of minus 80 ℃ for standby. After chloral hydrate is anesthetized, the mice are killed by a cervical spondylosis removal method, the outer skin of the abdomen of the mice is carefully cut off, the abdomen and the chest of the mice are cut off again by fixing with a pin, the liver and the kidney of the mice are taken out by forceps, the mice are repeatedly cleaned by using a precooled PBS solution, small tissues are cut off and fixed in a 10% neutral formalin solution (4% formaldehyde solution), and the rest tissues are frozen at the temperature of minus 80 ℃ for later use.

3 results of experiments

3.1 effects on mouse body weight: as shown in Table 12, the body weight of the experimental mice fluctuated within the Normal range for the duration of the experiment, and 57 (500,1000 mg/kg) had no significant effect on the body weight of both female and male C57BL/6 mice (P > 0.05) compared to the Normal group.

TABLE 12 influence of Compound 57 on mouse body weight

3.2 effects on the state of activity of mice: compared with Normal mice, 57 mice (500,1000 mg/kg) have relatively reduced activity after each administration, and the mice have poor spirit and can recover to be Normal after 1-2 hours; the mice showed no significant change in hair shine, behavioral activity, mental state, etc. compared with Normal group during 30 days of continuous observation.

3.3 effects on survival of mice:

TABLE 13 influence of Compound 57 on survival of mice

As shown in Table 13, 57 (500,1000 mg/kg) had no significant effect on the survival rate of female mice after 30 days of continuous administration. 57 (500,1000 mg/kg) after 30 days of continuous administration, none of the mice died, and the compound had no significant effect on the survival rate of male mice.

Claims

1. The application of the guaiane type sesquiterpene derivative or the pharmaceutically acceptable salt thereof in preparing the antitumor drug is characterized in that the guaiane type sesquiterpene derivative is shown as a general formula I:

wherein R is ₁ 、R ₂ Together form a double bond; or R is ₁ Is hydrogen or deuterium, R ₂ Is thatWherein R is ₃ And R is ₄ Respectively C ₁ ～C ₃ Alkyl, or R ₃ 、R ₄ And N atoms form a 5-6 membered ring structure, and the 5-6 membered ring structure is selected from pyrrole, proline, piperidine, piperazine and morpholine;

R ₅ is hydroxy, methoxy, methyl ester, halogen, or-OCONR ₆ R ₇ Wherein R is ₆ Is hydrogen, C ₁ ～C ₆ An alkyl group; r is R ₇ Is C ₁ ～C ₆ Alkyl, fluorine extractionSubstituted C ₁ ～C ₃ Alkyl, cyclopropane, hydroxy-substituted C ₁ ～C ₆ Alkyl, methoxy substituted C ₁ ～C ₆ Alkyl, dimethylaminoethyl and morpholine substituted C ₁ ～C ₆ Alkyl, piperazine substituted C ₁ ～C ₆ Alkyl, phenyl ring substituted methyl; or R is ₆ 、R ₇ And N atoms form a substituted 5-6 membered ring structure; or the 3-position carbon atom and the 4-position carbon atom are connected to form a double bond; or the 4-position carbon atom and the 5-position carbon atom are connected to form a double bond;

R ₈ is hydrogen or hydroxy;

2. The use according to claim 1, wherein the cancer is hepatocellular carcinoma, colorectal cancer or lymphoma.

3. The use according to claim 1, wherein the guaiane-type sesquiterpene derivative is represented by formula ii:

R ₁ 、R ₂ together form a double bond; or R is ₁ Is hydrogen or deuterium, R ₂ Is thatWherein R is ₃ And R is ₄ Respectively C ₁ ～C ₃ Alkyl, or R ₃ 、R ₄ And N atoms form a 5-6 membered ring structure, and the 5-6 membered ring structure is selected from pyrrole, proline, piperidine, piperazine and morpholine;

R ₅ is methyl; r is R ₆ Is hydroxy, methoxy, methyl ester, halogen; or the 3-position carbon atom and the 4-position carbon atom are connected to form a double bond; or carbon atoms at the 4-position and 5-positionA double bond is formed by connection;

R ₇ is hydrogen or hydroxy;

R ₈ is methyl; r is R ₉ And R is R ₁₀ The connection forms cyclopropane.

4. The use according to claim 1, wherein the guaiane-type sesquiterpene derivative is represented by general formula iii:

R ₅ is-OCONR ₆ R ₇ Wherein R is ₆ Is hydrogen, C ₁ ～C ₆ An alkyl group; r is R ₇ Is C ₁ ～C ₆ Alkyl, fluoro substituted C ₁ ～C ₃ Alkyl, cyclopropane, hydroxy-substituted C ₁ ～C ₆ Alkyl, methoxy substituted C ₁ ～C ₆ Alkyl, dimethylaminoethyl and morpholine substituted C ₁ ～C ₆ Alkyl, piperazine substituted C ₁ ～C ₆ Alkyl, phenyl ring substituted methyl; or R is ₆ 、R ₇ And N atoms form a substituted 5-to 6-membered ring structure.

5. The use according to claim 1, characterized in that the guaiane-type sesquiterpene derivatives are the following compounds:

6. the use according to claim 1, wherein the pharmaceutically acceptable salt comprises hydrochloride, sulfate, phosphate, maleate, fumaric or citrate.

7. The use according to claim 6, wherein the pharmaceutically acceptable salt is fumaric acid or hydrochloride:

8.a pharmaceutical composition comprising a guaiane-type sesquiterpene derivative according to claims 1-8 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, in combination with an immune checkpoint inhibitor.

9. The pharmaceutical composition of claim 8, wherein the combined immune checkpoint inhibitor is anti-PD-L1/PD-1 mab or anti-CTLA-4 mab.

10. Use of the pharmaceutical composition of claim 8 for the preparation of an antitumor drug.